ArticleOcular immunology and inflammation2025
The Therapeutic Effects of Purified Cortrophin Gel on Experimental Autoimmune Uveitis.
Article in Ocular immunology and inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeThe melanocortin pathways are central in maintaining the normal anti-inflammatory microenvironment of the eye. A repository corticotropin injection (RCI) from ANI Pharmaceuticals that activates multiple melanocortin pathways was studied for its effects on experimental autoimmune uveitis (EAU), a murine model of human endogenous uveitis.
methodsAt the chronic phase of EAU, the mice received an injection of the RCI. Clinical scoring of the eyes was conducted every 3 to 4 days using fundus microscopy until the uveitis resolved. The eyes were collected, sectioned, and H&E stained for histological scoring. A T-cell reaction assay was performed using spleen cells to measure IFN-g, IL-17, and IL-10 following restimulation with retinal antigen. The effects of the RCI's active pharmaceutical ingredient (API) on LPS-stimulated macrophage production of IL-1β, IL-10, and TNF-α were assessed by ELISA.
resultThe RCI in a dose-dependent manner suppressed the clinical scores of EAU, showing no significant difference in scoring between 400 U/kg of RCI and a group of native α-MSH-treated mice. In parallel, the retinas of the treated mice had a significant decrease in the histology scores. A significant reduction in IFN-γ and IL-17 production was observed in spleen T-cells of the treated EAU mice, with no regulatory immunity to retinal antigens. The API significantly suppressed the production of IL-1β, IL-10, and TNF-α by stimulated macrophages.
conclusionsRCI treatment effectively suppressed uveitis and protected the retina from inflammatory damage. These findings further illustrate the potential of melanocortin-based therapies for uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.